|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Fearon ER and Vogelstein B: A genetic
model for colorectal tumorigenesis. Cell. 61:759–767. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vogelstein B, Fearon ER, Hamilton SR, et
al: Genetic alterations during colorectal-tumor development. N Engl
J Med. 319:525–532. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Blank JL, Gerwins P, Elliott EM, Sather S
and Johnson GL: Molecular cloning of mitogen-activated protein/ERK
kinase kinases (MEKK) 2 and 3. Regulation of sequential
phosphorylation pathways involving mitogen-activated protein kinase
and c-Jun kinase. J Biol Chem. 271:5361–5368. 1996. View Article : Google Scholar
|
|
5
|
Su B, Cheng J, Yang J and Guo Z: MEKK2 is
required for T-cell receptor signals in JNK activation and
interleukin-2 gene expression. J Biol Chem. 276:14784–14790. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yao Z, Yoon S, Kalie E, Raviv Z and Seger
R: Calcium regulation of EGF-induced ERK5 activation: role of
Lad1-MEKK2 interaction. PLoS One. 5:e126272010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kato Y, Tapping RI, Huang S, Watson MH,
Ulevitch RJ and Lee JD: Bmk1/Erk5 is required for cell
proliferation induced by epidermal growth factor. Nature.
395:713–716. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cude K, Wang Y, Choi HJ, Hsuan SL, Zhang
H, Wang CY and Xia Z: Regulation of the G2-M cell cycle progression
by the ERK5-NFkappaB signaling pathway. J Cell Biol. 177:253–264.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gírio A, Montero JC, Pandiella A and
Chatterjee S: Erk5 is activated and acts as a survival factor in
mitosis. Cell Signal. 19:1964–1972. 2007.PubMed/NCBI
|
|
10
|
Pearson G, English JM, White MA and Cobb
MH: ERK5 and ERK2 cooperate to regulate NF-kappaB and cell
transformation. J Biol Chem. 276:7927–7931. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Montero JC, Ocaña A, Abad M, Ortiz-Ruiz
MJ, Pandiella A and Esparís-Ogando A: Expression of Erk5 in early
stage breast cancer and association with disease free survival
identifies this kinase as a potential therapeutic target. PLoS One.
4:e55652009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Carter EJ, Cosgrove RA, Gonzalez I,
Eisemann JH, Lovett FA, Cobb LJ and Pell JM: MEK5 and ERK5 are
mediators of the pro-myogenic actions of IGF-2. J Cell Sci.
122:3104–3112. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dinev D, Jordan BW, Neufeld B, Lee JD,
Lindemann D, Rapp UR and Ludwig S: Extracellular signal regulated
kinase 5 (ERK5) is required for the differentiation of muscle
cells. EMBO Rep. 2:829–834. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schramp M, Ying O, Kim TY and Martin GS:
ERK5 promotes Src-induced podosome formation by limiting Rho
activation. J Cell Biol. 181:1195–1210. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Spiering D, Schmolke M, Ohnesorge N, et
al: MEK5/ERK5 signaling modulates endothelial cell migration and
focal contact turnover. J Biol Chem. 284:24972–24980. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Watson FL, Heerssen HM, Bhattacharyya A,
Klesse L, Lin MZ and Segal RA: Neurotrophins use the Erk5 pathway
to mediate a retrograde survival response. Nat Neurosci. 4:981–988.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sohn SJ, Sarvis BK, Cado D and Winoto A:
ERK5 MAPK regulates embryonic angiogenesis and acts as a
hypoxia-sensitive repressor of vascular endothelial growth factor
expression. J Biol Chem. 277:43344–43351. 2002. View Article : Google Scholar
|
|
18
|
Nicol RL, Frey N, Pearson G, Cobb M,
Richardson J and Olson EN: Activated MEK5 induces serial assembly
of sarcomeres and eccentric cardiac hypertrophy. EMBO J.
20:2757–2767. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu L, Cundiff P, Abel G, et al:
Extracellular signal-regulated kinase (ERK) 5 is necessary and
sufficient to specify cortical neuronal fate. Proc Natl Acad Sci
USA. 103:9697–9702. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nishimoto S and Nishida E: MAPK
signalling: ERK5 versus ERK1/2. EMBO Rep. 7:782–786. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang X and Tournier C: Regulation of
cellular functions by the ERK5 signalling pathway. Cell Signal.
18:753–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun W, Wei X, Kesavan K, et al: MEK kinase
2 and the adaptor protein Lad regulate extracellular
signal-regulated kinase 5 activation by epidermal growth factor via
Src. Mol Cell Biol. 23:2298–2308. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kesavan K, Lobel-Rice K, Sun W, Lapadat R,
Webb S, Johnson GL and Garrington TP: MEKK2 regulates the
coordinate activation of ERK5 and JNK in response to FGF-2 in
fibroblasts. J Cell Physiol. 199:140–148. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Herbst RS and Shin DM: Monoclonal
antibodies to target epidermal growth factor receptor-positive
tumors: a new paradigm for cancer therapy. Cancer. 94:1593–1611.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Billottet C, Elkhatib N, Thiery JP and
Jouanneau J: Targets of fibroblast growth factor 1 (FGF-1) and
FGF-2 signaling involved in the invasive and tumorigenic behavior
of carcinoma cells. Mol Biol Cell. 15:4725–4734. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cazares LH, Troyer D, Mendrinos S, et al:
Imaging mass spectrometry of a specific fragment of
mitogen-activated protein kinase/extracellular signal-regulated
kinase kinase kinase 2 discriminates cancer from uninvolved
prostate tissue. Clin Cancer Res. 15:5541–5551. 2009. View Article : Google Scholar
|
|
27
|
Cheng J, Zhang D, Kim K, Zhao Y, Zhao Y
and Su B: Mip1, an MEKK2-interacting protein, controls MEKK2
dimerization and activation. Mol Cell Biol. 25:5955–5964. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cheng J, Yu L, Zhang D, Huang Q, Spencer D
and Su B: Dimerization through the catalytic domain is essential
for MEKK2 activation. J Biol Chem. 280:13477–13482. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
McCracken SR, Ramsay A, Heer R, et al:
Aberrant expression of extracellular signal-regulated kinase 5 in
human prostate cancer. Oncogene. 27:2978–2988. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sticht C, Freier K, Knöpfle K, et al:
Activation of MAP kinase signaling through ERK5 but not ERK1
expression is associated with lymph node metastases in oral
squamous cell carcinoma (OSCC). Neoplasia. 10:462–470.
2008.PubMed/NCBI
|
